Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefit of adjuvant chemotherapy in ER positive, HER2 negative, early stage breast cancer. As health literacy and numeracy skills in the general population are poor, healthcare professionals (HCPs) require a wide repertoire of communication skills to explain clearly risk of recurrence scores (RSs) and uncertainty. We developed and evaluated an educational program for HCPs discussing GEP test results and adjuvant treatment. Methods: Eight hour workshops contained elements aimed at improving knowledge, communication skills, and self-awareness; these included:- the science underpinning GEP tests, an interactive risk psychology lecture, exercises an...
Purpose This systematic review examined educational training interventions for healthcare professi...
Objective Chemotherapy side‐effects can be substantial. There is increasing recognition that some o...
ABSTRACTBackground: National guidelines recommend cancer genetic risk assessment (CGRA) (i.e. geneti...
Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefi...
Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefi...
Purpose To compare participants’ knowledge about gene expression profiling (GEP) tests and recurren...
Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recur...
Abstract: Background: Gene expression profiling (GEP) is increasingly used in the rapidly evolving f...
Background: New genomic technology now allows physi-cians to provide women with individualized and h...
Doctors commonly use genomic testing for breast cancer recurrence risk. We sought to assess whether ...
Purpose To compare participants’ knowledge about gene expression profiling (GEP) tests and recurren...
We sought to examine how patients’ treatment decisions incorporate potentially conflicting informati...
Background: Genomic techniques are being developed within oncology and beginning to be experienced...
Background: Genomic recurrence risk test results now inform clinical decisions about adjuvant treatm...
Background Genomic techniques are being developed within oncology and beginning to be experienced w...
Purpose This systematic review examined educational training interventions for healthcare professi...
Objective Chemotherapy side‐effects can be substantial. There is increasing recognition that some o...
ABSTRACTBackground: National guidelines recommend cancer genetic risk assessment (CGRA) (i.e. geneti...
Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefi...
Purpose: Gene expression profiling (GEP) test scores calculate risks of recurrence and likely benefi...
Purpose To compare participants’ knowledge about gene expression profiling (GEP) tests and recurren...
Practice guidelines incorporate genomic tumor profiling, using results such as the Oncotype DX Recur...
Abstract: Background: Gene expression profiling (GEP) is increasingly used in the rapidly evolving f...
Background: New genomic technology now allows physi-cians to provide women with individualized and h...
Doctors commonly use genomic testing for breast cancer recurrence risk. We sought to assess whether ...
Purpose To compare participants’ knowledge about gene expression profiling (GEP) tests and recurren...
We sought to examine how patients’ treatment decisions incorporate potentially conflicting informati...
Background: Genomic techniques are being developed within oncology and beginning to be experienced...
Background: Genomic recurrence risk test results now inform clinical decisions about adjuvant treatm...
Background Genomic techniques are being developed within oncology and beginning to be experienced w...
Purpose This systematic review examined educational training interventions for healthcare professi...
Objective Chemotherapy side‐effects can be substantial. There is increasing recognition that some o...
ABSTRACTBackground: National guidelines recommend cancer genetic risk assessment (CGRA) (i.e. geneti...